Novo Nordisk Q3 results: Ozempic maker’s profit falls 27%; cuts 9,000 jobs
Novo Nordisk, maker of Ozempic and Wegovy, lowered its 2025 sales outlook for the fourth time, citing slower growth in diabetes and obesity treatments. The ...
‘To provide clarity on future governance’: Ozempic-maker Novo Nordisk to shake up board; move comes after 9,000 layoffs
Novo Nordisk Reshapes Its Leadership: Charting a Course for the Future The Danish pharmaceutical behemoth, Novo Nordisk, the name now synonymous with the groundbreaking weight-loss ...
Novo Nordisk to cut 9,000 jobs: Ozempic maker to reduce workforce by 11%; refocus on diabetes and obesity treatments
Novo Nordisk is set to reduce its workforce by 11%, eliminating 9,000 jobs globally, including 5,000 in Denmark, to save $1.3 billion amid rising competition ...
